TenNor Therapeutics sets 8 June 2026 board meeting to weigh potential final dividend

Bulletin Express

05/27

TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final dividend, if any, for the most recent financial year.

As disclosed, the current board consists of one executive director—Chairman and CEO Dr. Ma Zhenkun—two non-executive directors, Dr. Song Gaoguang and Mr. Michael James Bakes, and three independent non-executive directors, Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping.

The notice, released in Hong Kong on 27 May 2026, indicates that further details, including any dividend proposal, will follow the board’s deliberations. Investors and stakeholders are advised to monitor subsequent announcements for the board’s final resolution.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1103043142"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103043142\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103043142?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103043142","market":"us","top_or_hot":-1,"title":"TenNor Therapeutics sets 8 June 2026 board meeting to weigh potential final dividend","media":"Bulletin Express","content":"<p>TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final dividend, if any, for the most recent financial year.</p>\n<p>As disclosed, the current board consists of one executive director—Chairman and CEO Dr. Ma Zhenkun—two non-executive directors, Dr. Song Gaoguang and Mr. Michael James Bakes, and three independent non-executive directors, Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping.</p>\n<p>The notice, released in Hong Kong on 27 May 2026, indicates that further details, including any dividend proposal, will follow the board’s deliberations. Investors and stakeholders are advised to monitor subsequent announcements for the board’s final resolution.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics sets 8 June 2026 board meeting to weigh potential final dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics sets 8 June 2026 board meeting to weigh potential final dividend\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-05-27 18:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final dividend, if any, for the most recent financial year.</p>\n<p>As disclosed, the current board consists of one executive director—Chairman and CEO Dr. Ma Zhenkun—two non-executive directors, Dr. Song Gaoguang and Mr. Michael James Bakes, and three independent non-executive directors, Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping.</p>\n<p>The notice, released in Hong Kong on 27 May 2026, indicates that further details, including any dividend proposal, will follow the board’s deliberations. Investors and stakeholders are advised to monitor subsequent announcements for the board’s final resolution.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹諾醫藥-B","start_time":0,"source_url":"","article_id":"1103043142","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103043142","pubTimestamp":1779877383,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"TenNor Therapeutics定于2026年6月8日召开董事会会议，权衡潜在的末期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final dividend, if any, for the most recent financial year.\nAs disclosed, the current board consists of one executive director—Chairman and CEO Dr. Ma Zhenkun—two non-executive directors, Dr. Song Gaoguang and Mr. Michael James Bakes, and three independent non-executive directors, Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping.\nThe notice, released in Hong Kong on 27 May 2026, indicates that further details, including any dividend proposal, will follow the board’s deliberations. Investors and stakeholders are advised to monitor subsequent announcements for the board’s final resolution.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}